Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Active, not recruiting · NCT02159755 · Registry updated 2026-05-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 1 | 2026-05-27 | NCT02159755 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NYP/Weill Cornell Medical Center | New York | United States | 128 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 243 |
| Washington University School of Medicine | St Louis | United States | 895 |